DURHAM … Pharmaceutical research company Quintiles Transnational (Nasdaq: QTRN) has replaced two people on its nine-member board of directors.

Pamela J. Kirby, Quintiles chief executive officer, and Dr. William L. Roper, dean of the School of Public Health at the University of North Carolina at Chapel Hill, have joined the board. They replace Dr. Eric J. Topol, who has served on the board since 1997, and Jim D. Kever, principal of Voyent Partners LLC, who has served since 1999. Neither Topol nor Kever chose to stand for re-election.

“We welcome Bill and Pam to our board of directors and extend our best wishes to Eric and Jim,” Quintiles Chairman Dennis Gillings says in a statement. “Eric Topol’s experience with large-scale global clinical trials and his medical perspective have helped us enhance our corporate policies and quality standards. Jim Kever’s participation has been particularly constructive in the development of written ethics standards.”

Roper is a member of the Institute of Medicine of the National Academy of Sciences and serves on the Institute of Medicine governing council. He is chairman of the board of Partnership for Prevention, vice-chairman of the board of the National Quality Forum, a member of the board of trustees of the Robert Wood Johnson Foundation and a member of the boards of Luminex, DaVita and the UNC Health Care System.

He previously was senior vice president of Prudential HealthCare. He joined Prudential in 1993 as president of the Prudential Center for Health Care Research. Prior to that, Roper was director of the Centers for Disease Control and Prevention and was administrator of the Health Care Financing Administration. He received his medical degree from the University of Alabama School of Medicine and his master’s degree in public health from the University of Alabama at Birmingham School of Public Health.

Kirby was appointed Quintiles CEO in April 2001. She is responsible for all operational and administrative functions and reports directly to Gillings. She received a bachelor’s degree in clinical pharmacology in 1975 and a doctorate in clinical pharmacology in 1978, both from the University of London.

During her career, which includes 17 years with Astra, Kirby has held key executive positions in senior operations management, business development, global marketing and research and development. Prior to joining Quintiles, Kirby headed global strategic marketing and business development for the pharmaceuticals division of F. Hoffman-La Roche. She is a member of the board of Smith & Nephew plc.

Quintiles website: www.quintiles.com